Literature DB >> 32072586

Defining Efficacy Estimands in Clinical Trials: Examples Illustrating ICH E9(R1) Guidelines.

Bohdana Ratitch1, Niti Goel2,3, Craig Mallinckrodt4, James Bell5, Jonathan W Bartlett6, Geert Molenberghs7, Pritibha Singh8, Ilya Lipkovich9, Michael O'Kelly10.   

Abstract

This paper provides examples of defining estimands in real-world scenarios following ICH E9(R1) guidelines. Detailed discussions on choosing the estimands and estimators can be found in our companion papers. Three scenarios of increasing complexity are illustrated. The first example is a proof-of-concept trial in major depressive disorder where the estimand is chosen to support the sponsor decision on whether to continue development. The second and third examples are confirmatory trials in severe asthma and rheumatoid arthritis respectively. We discuss the intercurrent events expected during each trial and how they can be handled so as to be consistent with the study objectives. The estimands discussed in these examples are not the only acceptable choices for their respective scenarios. The intent is to illustrate the key concepts rather than focus on specific choices. Emphasis is placed on following a study development process where estimands link the study objectives with data collection and analysis in a coherent manner, thereby avoiding disconnect between objectives, estimands, and analyses.

Entities:  

Keywords:  clinical trials; estimands; intercurrent events

Mesh:

Year:  2020        PMID: 32072586     DOI: 10.1007/s43441-019-00065-7

Source DB:  PubMed          Journal:  Ther Innov Regul Sci        ISSN: 2168-4790            Impact factor:   1.778


  6 in total

1.  Treatment estimands in clinical trials of patients hospitalised for COVID-19: ensuring trials ask the right questions.

Authors:  Brennan C Kahan; Tim P Morris; Ian R White; Conor D Tweed; Suzie Cro; Darren Dahly; Tra My Pham; Hanif Esmail; Abdel Babiker; James R Carpenter
Journal:  BMC Med       Date:  2020-09-09       Impact factor: 8.775

2.  Inclusion of non-inferiority analysis in superiority-based clinical trials with single-arm, two-stage Simon's design.

Authors:  Miguel Sampayo-Cordero; Bernat Miguel-Huguet; José Pérez-García; David Páez; Ángel L Guerrero-Zotano; Javier Garde-Noguera; Elena Aguirre; Esther Holgado; Elena López-Miranda; Xin Huang; Andrea Malfettone; Antonio Llombart-Cussac; Javier Cortés
Journal:  Contemp Clin Trials Commun       Date:  2020-11-28

Review 3.  Functional Loss and Mortality in Randomized Clinical Trials for Amyotrophic Lateral Sclerosis: To Combine, or Not to Combine-That is the Estimand.

Authors:  Ruben P A van Eijk; Kit C B Roes; Inez de Greef-van der Sandt; Leonard H van den Berg; Ying Lu
Journal:  Clin Pharmacol Ther       Date:  2022-02-17       Impact factor: 6.903

4.  Marking 2-Years of New Thinking in Clinical Trials: The Estimand Journey.

Authors:  C Fletcher; N Hefting; M Wright; J Bell; J Anzures-Cabrera; D Wright; H Lynggaard; A Schueler
Journal:  Ther Innov Regul Sci       Date:  2022-04-24       Impact factor: 1.337

5.  Rethinking intercurrent events in defining estimands for tuberculosis trials.

Authors:  Tra My Pham; Conor D Tweed; James R Carpenter; Brennan C Kahan; Andrew J Nunn; Angela M Crook; Hanif Esmail; Ruth Goodall; Patrick Pj Phillips; Ian R White
Journal:  Clin Trials       Date:  2022-07-19       Impact factor: 2.599

6.  Investigation of the efficacy of the short regimen for rifampicin-resistant TB from the STREAM trial.

Authors:  P P J Phillips; A Van Deun; S Ahmed; R L Goodall; S K Meredith; F Conradie; C-Y Chiang; I D Rusen; A J Nunn
Journal:  BMC Med       Date:  2020-11-04       Impact factor: 8.775

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.